Search Cancer Clinical Trials

Mass General Cancer Center offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
Search by condition
Search By:
16 results
  • Lung Cancer, Head and Neck Cancer, Bladder Cancer, Melanoma

18-418          Phase III

A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial.

  • Prostate Cancer, Pancreatic Cancer, Ovarian Cancer, Lung Cancer, Head and Neck Cancer, Esophageal Cancer, Cervical Cancer, Breast Cancer, Bladder Cancer

24-114          Phase I

A Phase 1 Trial Investigating LY4101174, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants with Recurrent, Advanced or Metastatic Solid Tumors

  • Prostate Cancer, Lung Cancer, Colorectal Cancer, Breast Cancer, Bladder Cancer

23-452          Phase I

A Phase 1, First-in-Human, Dose Escalation and Expansion Study of FX-909 in Patients with Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma

  • Melanoma, Lung Cancer, Head and Neck Cancer, Bladder Cancer, Metastatic/Advanced Cancer

17-330          Phase I

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

  • Uterine Cancer, Ovarian Cancer, Melanoma, Breast Cancer, Lung Cancer, Endometrial Cancer, Bladder Cancer

22-430          Phase II

A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-F106C as a Single Agent and in Combination with Checkpoint Inhibitors in HLA-A*02:01-Positive Participants with Advanced PRAME-Positive Cancers

  • Bladder Cancer, Endometrial Cancer, Esophageal Cancer, Gastric (Stomach) Cancer, Liver Cancer, Pancreatic Cancer, Sarcoma

20-544          Phase II

A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients with Advanced Solid Tumors Harboring a p53 Y220C Mutation

  • Liver Cancer, Endometrial Cancer, Bladder Cancer, Breast Cancer

24-666          Phase II

A Phase 1/2 Study of a Selective FGFR2/3 Inhibitor, CGT4859, in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors Harboring FGFR2 and/or FGFR3 Genetic Alterations

  • Gastric (Stomach) Cancer, Ovarian Cancer, Bladder Cancer, Breast Cancer, Esophageal Cancer, Lung Cancer

23-679          Phase II

A Phase 1/2 Study of PRO1107 in Patients with Advanced Solid Tumors

  • Ovarian Cancer, Head and Neck Cancer, Melanoma, Breast Cancer, Lung Cancer, Bladder Cancer, Kidney Cancer

21-329          Phase II

A Phase 1a Open-Label, Dose-Escalation, and a Phase 2 Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of ST-067 Administered Subcutaneously as Monotherapy in Patients with Relapsed or Refractory Solid Tumors

  • Breast Cancer, Cervical Cancer, Esophageal Cancer, Head and Neck Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Bladder Cancer

24-353          Phase I

A Phase 1a/1b Study of LY4052031, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants with Advanced or Metastatic Urothelial Carcinoma or Other Solid Tumors

Showing 1 - 10 of 16 results